AbbVie/Roche’s Venclexta wins fourth approval; WuXi, fellow CRO Altasciences ink deal

Michael Severino

AbbVie and Roche’s blood cancer drug, Venclexta, has notched a fourth approval. On Wednesday, AbbVie $ABBV said the drug was approved in combination with Genentech’s Gazyva for treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). “The approval is based on findings from the CLL14 trial in which patients received a 12-month treatment regimen. The majority of patients receiving Venclexta in the trial remained progression-free at two years,” said Michael Severino, AbbVie’s vice chairman and president, in a statement. Venclexta was first approved in 2016 by the FDA under the accelerated approval pathway for use in certain patients with CLL — it is now sanctioned for use in more than 50 countries and generated $344 million in global sales last year.

Edward Hu

→ Well-connected China-based CRO WuXi has joined forces with a Canadian CRO, Altasciences. The Laval, Quebec-based company will support WuXi AppTec’s Investigational New Drug (WIND) platform — no financial details of the deal were disclosed. “The partnership is an excellent complement for WuXi to help our global collaborators to expedite the R&D process from pre-IND to clinical stages and bring better therapies to patients far faster,” said Edward Hu, Co-CEO at WuXi AppTec, in a statement. Meanwhile, Wuxi’s biologics arm kicked off the construction of a 1.3 million sq. ft. manufacturing center in Chengdu — one of the largest cities in Southwest China — on Thursday. 

→ Oncology drug developer Cellectar Biosciences $CLRB has unveiled a $10 million offering—  with institutional investors buying $5 million in a registered direct offering of 1,982,000 common shares, and the remaining $5 million coming from a concurrent private placement of 2,018,000 common shares. The announcement comes days after the company’s lead drug — CLR 131 — was granted fast track status by the FDA for fourth-line or later treatment of relapse/refractory multiple myeloma, and one day after the treatment induced a positive response in an ongoing Phase I multiple myeloma study.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->